Showing results (1-10 of 194) with videos related to
Sort By:
Pageof 20
Best Practice & Research. Clinical Haematology|March 14, 2012
New insights into the biology of molecular subtypes of diffuse large B-cell lymphoma and Burkitt lymphomaMareike Frick, Bernd Dörken, Georg LenzJournal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 13, 2011
Pathogenesis of non-Hodgkin's lymphomaHendrik Nogai, Bernd Dörken, Georg LenzCell Cycle (Georgetown, Tex.)|May 12, 2006
Reprogramming of B lymphoid cells in human lymphoma pathogenesisMartin Janz, Bernd Dörken, Stephan MathasTherapeutic Advances in Hematology|April 5, 2013
The molecular biology of diffuse large B-cell lymphomaMareike Frick, Bernd Dörken, Georg LenzCurrent Molecular Medicine|February 22, 2008
Notch signaling in leukemias and lymphomasFranziska Jundt, Rolf Schwarzer, Bernd DörkenThe Journal of Clinical Investigation|January 15, 2004
Cellular senescence in cancer treatment: friend or foe?Pascal Kahlem, Bernd Dörken, Clemens A SchmittBiochimica Et Biophysica Acta|January 21, 2004
Downregulation of genes involved in DNA repair and differential expression of transcription regulators and phosphatases precede IgM-induced apoptosis in the Burkitt's lymphoma cell line BL60-2Barbara Schories, Martin Janz, Bernd Dörken, et al.International Journal of Cancer|November 22, 2007
Transcriptional regulation of human survivin by early growth response (Egr)-1 transcription factorMandy Wagner, Karin Schmelz, Bernd Dörken, et al.Expert Review of Hematology|November 19, 2010
Nilotinib for the treatment of chronic myeloid leukemiaTheo Daniel Kim, Bernd Dörken, Philipp le CoutreInternational Journal of Cancer|December 21, 2004
5-Aza-2'-deoxycytidine induces p21WAF expression by demethylation of p73 leading to p53-independent apoptosis in myeloid leukemiaKarin Schmelz, Mandy Wagner, Bernd Dörken, et al.Pageof 20